SCHEMBL13777063

SCHEMBL13777063

CCOC1C(O)[C@H](n2cnc3c(N)ncnc32)O[C@@H]1CO

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 4/20 0.72
▸ ADORA1 P30542 3/20 0.72
▸ SMN1; SMN2 Q16637 2/20 0.72
▸ DPP4 P27487 1/20 0.72
▸ MEN1 O00255 1/20 0.72
▸ SLC28A1 O00337 1/20 0.72
▸ MAP3K7 O43318 1/20 0.72
▸ SLC28A2 O43868 1/20 0.72
▸ GAPDH P04406 1/20 0.72
▸ MAPK1 P28482 1/20 0.72
▸ ADORA2A P29274 1/20 0.72
▸ ADORA2B P29275 1/20 0.72
▸ STAT6 P42226 1/20 0.72
▸ PI4KA P42356 1/20 0.72
▸ KMT2A Q03164 1/20 0.72
▸ PI4K2B Q8TCG2 1/20 0.72
▸ DOT1L Q8TEK3 1/20 0.72
▸ SLC29A1 Q99808 1/20 0.72
▸ PI4K2A Q9BTU6 1/20 0.72
▸ SLC28A3 Q9HAS3 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5559352 0.92 ADORA3 (0.72) ADORA3ADORA1SMN1; SMN2DPP4MEN1
SCHEMBL29722344 0.92 ADORA3 (0.72) ADORA3ADORA1SMN1; SMN2DPP4MEN1
SCHEMBL6898326 0.92 ADORA3 (0.72) ADORA3ADORA1SMN1; SMN2DPP4MEN1
SCHEMBL10589732 0.90 EHMT1 (0.68) ADORA3ADORA1SMN1; SMN2DPP4MEN1
SCHEMBL5220384 0.90 ADORA3 (0.69) ADORA3ADORA1SMN1; SMN2DPP4MEN1
SCHEMBL5220374 0.90 ADORA3 (0.69) ADORA3ADORA1SMN1; SMN2DPP4MEN1
SCHEMBL31139492 0.90 ADORA3 (0.69) ADORA3ADORA1SMN1; SMN2DPP4MEN1
SCHEMBL13064102 0.89 ADORA3 (0.72) ADORA3ADORA1SMN1; SMN2DPP4MEN1
SCHEMBL13020621 0.89 GAA (0.70) ADORA3ADORA1SMN1; SMN2DPP4MEN1
SCHEMBL23547979 0.89 ADORA3 (0.75) ADORA3ADORA1SMN1; SMN2DPP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181921-A1 2-5A ANALOGS AND THEIR METHODS OF USE ALIOS BIOPHARMA INC. (US) 2009-07-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181921-A1 2-5A ANALOGS AND THEIR METHODS OF USE RNASEL, RNASE1, RNASEH1 ADORA3 1297/4885ADORA1 1828/4885SMN1; SMN2 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback